{
    "clinical_study": {
        "@rank": "144795", 
        "arm_group": {
            "arm_group_label": "No treatment", 
            "description": "Diffuse Optical Spectroscopy"
        }, 
        "brief_summary": {
            "textblock": "The first step in any clinical intervention against obesity involves sustained lifestyle\n      changes. Researcher can use these strategies to beneficial the effects of weight and on\n      cardiovascular risk. The researcher develope methods for assessing the effectiveness use\n      optical technology to make such assessments, specifically in the area of fatty tissue can\n      predict the effectiveness of the intervention in causing weight reduction and treating\n      metabolic disease."
        }, 
        "brief_title": "The Use of Diffuse Optical Spectroscopy to Characterizein Response to Weight-Loss Intervention", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Overweight", 
        "condition_browse": {
            "mesh_term": [
                "Weight Loss", 
                "Overweight"
            ]
        }, 
        "detailed_description": {
            "textblock": "Optical technologies under development at the Beckman Laser Institute.\n\n      Diffuse Optical Spectroscopy Imaging is a method for studying absorption and scattering\n      (optical properties) of tissue in humans. It is related to near-infrared spectroscopy , but\n      allows for more quantitative and thorough measurements. The researcher use Diffuse Optical\n      Spectroscopy to measure fatty tissue, water, blood concentration levael during weight loss\n      program to determine the effect of sustained changes in weight or relapses."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Body Mass Index greater than 25 (overweight)\n\n          -  Participation in UCI Weight Loss program (Either Preventative Cardiology, or Weight\n             Management Program)\n\n        Exclusion Criteria:\n\n          -  A medical history of myocardial infarction or cerebrovascular stroke\n\n          -  Pregnancy or planned pregnancy during the course of the study period"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "1. Male or female 18 to 65 years of age\n\n          2. Body Mass Index greater than 25 (overweight)\n\n          3. Participation in UCI Weight Loss program (Either Preventative Cardiology, or Weight\n             Management Program)"
            }
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02146885", 
            "org_study_id": "LAMMP-DOS-30139"
        }, 
        "intervention": {
            "arm_group_label": "No treatment", 
            "description": "No treatment", 
            "intervention_name": "Diffuse Optical Spectroscopy", 
            "intervention_type": "Other", 
            "other_name": "Diffuse Optical Spectroscopy"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 20, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Irvine", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92612"
                }, 
                "name": "Beckman Laser Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "The Use of Diffuse Optical Spectroscopy to Characterize Adipose Tissue Oxygenation and Vascular Reactivity in Response to Weight-Loss Intervention", 
        "overall_official": {
            "affiliation": "Beckman Laser Institute, UCI", 
            "last_name": "Shaista Malik, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The preventative cardiology program aims to help patients reduce body weight by a significant amount (at least 10%).", 
            "measure": "Preventative Cardiology Program by reduce body weight", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02146885"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of California, Irvine", 
            "investigator_full_name": "Montana Compton", 
            "investigator_title": "Research Nurse Coordinator", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "University of California, Irvine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Montana Compton", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Cross-Sectional", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "3 Months", 
        "verification_date": "May 2014"
    }
}